This article is sponsored by SCIEX.

A new era of medicine has entered clinics with drugs against sickle cell anaemia or gene-related deafness, and many more gene therapy drugs are in different stages of development. These novel approaches go beyond treating symptoms; they aim to cure diseases. However, the diversity and complexity of gene therapies create challenges for developers.

How should the different delivery systems, such as viral vectors or nanoparticles, and the range of drug substances, such as RNAs, DNAs and proteins, be assessed?

While time-to-market is of the essence, no shortcuts can be taken when ensuring quality and proving safety and efficacy. The complexity and novelty of these modalities demand continuous adaptability, innovative thinking and the development of advanced analytical technologies to address urgent questions.

Many gene therapies share a common starting material: plasmid DNA (pDNA). pDNA is needed, for instance, to manufacture viral vectors with the desired gene of interest and messenger RNA (mRNA), such as CRISPR-encoding mRNA. Frequently, slab gels are used to assess pDNA purity but lack quantitative accuracy and automatisation capabilities. In September 2024, SCIEX launched the DNA 20 kb Plasmid and Linear kit—a new kit-based solution for capillary electrophoresis (CE) systems to help address these challenges. With a ready-to-use solution for plasmid sizes from 2-19 kilobases, plasmids for complex viral vectors and mRNAs can be assessed with one quantitative CE method that can be automated.

The same CE systems can be subsequently used to understand the quality attributes of viral vectors, mRNA and guide RNAs. While multipurpose usage was sometimes overlooked, limited lab space and investments are putting a higher focus on versatility. Apart from providing pDNA purity, size, and identity information, SCIEX CE solutions can be leveraged for viral vector analysis. Viral genome integrity, capsid protein integrity, size and ratio information can be obtained with intuitive kit-based assays. For mRNA-based therapies, the same instrumentation enables scientists to assess mRNA integrity, purity and size with high resolution. Understanding mRNA purity in more depth through higher resolution can be leveraged to link functional data more effectively.

Recently, SCIEX and Replicate Bioscience, Inc. co-published a method for assessing large self-replicating RNA (srRNA). The 16 kb RNA molecule was successfully separated from degradation products and other impurities.

Apart from integrity, purity and size, the poly(A) tail of mRNA is a critical quality attribute, impacting stability and translation efficiency. Approaches based on liquid chromatography struggled with the resolution of these large, repetitive components. Researchers from Regeneron leveraged the PA 800 Plus system to achieve single-nucleotide resolution for poly(A) tails of ~120 nucleotides (nt) and published their method late last year. Detailed method parameters for achieving single-nucleotide resolution for poly(A) tails were also published by SCIEX to support the scientific community in their analysis efforts.

For CRISPR-based gene editing approaches, guide RNAs (gRNAs) are often co-delivered with mRNA encoding for Cas enzymes to enable specific cuts in the genome. The synthetic gRNA can vary in size and complexity. Confirming the size, integrity and purity of these large synthetic molecules requires high-resolving analysis techniques. Prime-editing guide RNAs pose additional analytical challenges; their complementary bases can lead to secondary structure formation resistant to common denaturation strategies. Integrated DNA Technologies and SCIEX overcame these issues by developing an assay with high-temperature CE separation. This was enabled by liquid-controlled temperature in the SCIEX CE system and tested on various pegRNAs ranging from 179 nt to 219 nt.

The versatility of analytical solutions is crucial for the assessment of cell and gene therapies and in preparation for the future. However, more than one technology is needed to evaluate these complex molecules and drug products thoroughly. A highly adaptable, orthogonal technique is mass spectrometry (MS). It has proven to be extremely valuable to better understand gene editing effects by studying off-target effects, which other assays can easily be blind towards. More recently, the impact of lipid impurities on the cargo of lipid nanoparticles (LNP) was put into focus for medicines based on non-viral delivery. Researchers at Moderna discovered a correlation between N-oxide impurities and the loss of function of mRNA in 2021.  Investigations that followed, using electron-activated dissociation (EAD) on a ZenoTOF 7600 system, showed the ability to distinguish between harmful N-oxides and other impurities, as Dr. Adam Crowe explains in his presentation in more detail.

Our goal is to enable you to push the boundaries of analytics and move past analytical challenges. At SCIEX, we are a team dedicated to helping revolutionise medicine with CE and MS solutions.

Contact SCIEX for more information.